Lista de obras - Richard W. Joseph - Dominio Público Uruguay

A Multidisciplinary Biospecimen Bank of Renal Cell Carcinomas Compatible with Discovery Platforms at Mayo Clinic, Scottsdale, Arizona

artículo científico publicado en 2015

A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer.

artículo científico publicado en 2016

A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma.

artículo científico publicado en 2012

ANKS1B is a smoking-related molecular alteration in clear cell renal cell carcinoma.

artículo científico publicado en 2014

Age-period-cohort analysis of renal cell carcinoma in United States adults

artículo científico publicado en 2013

An integrated model of the transcriptome of HER2-positive breast cancer

artículo científico publicado en 2013

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

artículo científico publicado en 2014

Assessing the clinical use of clear cell renal cell carcinoma molecular subtypes identified by RNA expression analysis.

artículo científico publicado en 2014

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

artículo científico publicado en 2016

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

artículo científico publicado en 2016

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

artículo científico publicado en 2016

BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor.

artículo científico publicado en 2017

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

article

Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2

Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression.

artículo científico publicado en 2015

Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness.

artículo científico publicado en 2016

Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response.

artículo científico publicado en 2015

Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced Melanoma ⬇️

artículo científico publicado el 1 de enero de 2012

Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy.

artículo científico publicado en 2015

Detection of tumor-associated cells in cryopreserved peripheral blood mononuclear cell samples for retrospective analysis.

artículo científico publicado en 2016

Efficacy of immunotherapy for metastatic mucosal melanoma.

artículo científico publicado en 2016

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

artículo científico publicado en 2016

Evaluation of the association of prostate cancer-specific anxiety with sexual function, depression and cancer aggressiveness in men 1 year following surgical treatment for localized prostate cancer.

artículo científico publicado en 2012

Follicular Dendritic Cell Sarcoma Presenting As a Thyroid Mass

artículo científico publicado en 2014

High incidence of vitamin D deficiency in patients undergoing allogeneic stem cell transplantation

artículo científico publicado en 2011

High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma

artículo científico publicado en 2015

Higher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma

artículo científico publicado en 2013

Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy

artículo científico publicado en 2011

Inverse association between programmed death ligand 1 and genes in the VEGF pathway in primary clear cell renal cell carcinoma

artículo científico publicado en 2013

Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma

artículo científico publicado en 2017

Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy.

artículo científico publicado en 2014

Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma

artículo científico publicado en 2013

Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma

artículo científico publicado en 2014

Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death

artículo científico publicado en 2015

Management of Metastatic Apocrine Hidradenocarcinoma with Chemotherapy and Radiation

artículo científico publicado en 2015

NRAS mutation status is an independent prognostic factor in metastatic melanoma

artículo científico publicado en 2012

Negative Sentinel Lymph Node Biopsy in Merkel Cell Carcinoma is Associated with a Low Risk of Same-Nodal-Basin Recurrences.

artículo científico publicado en 2015

Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice.

artículo científico publicado en 2017

Obese men have more advanced and more aggressive prostate cancer at time of surgery than non-obese men after adjusting for screening PSA level and age: results from two independent nested case-control studies

artículo científico publicado en 2013

Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma

artículo científico publicado en 2012

PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation

artículo científico publicado en 2015

Patient-derived tumor xenograft models for melanoma drug discovery

artículo científico publicado en 2016

Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team.

artículo científico

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma

artículo científico publicado en 2016

Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab

artículo científico publicado en 2016

Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma

artículo científico publicado en 2018

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

artículo científico publicado en 2013

Sentinel lymph node biopsy in Merkel cell carcinoma: The Mayo Clinic experience of 150 patients

artículo científico publicado en 2017

Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy.

artículo científico publicado en 2013

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma

artículo científico publicado en 2016

Somatic expression of ENRAGE is associated with obesity status among patients with clear cell renal cell carcinoma

artículo científico publicado en 2013

Steroid hormone influence on melanomagenesis

artículo científico

Therapy for metastatic melanoma: the past, present, and future.

artículo científico publicado en 2012

Three hundred consecutive emergent celiotomies in general surgery patients: influence of advanced diagnostic imaging techniques and procedures on diagnosis

artículo científico publicado en 2002

Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod

scientific article published on 01 August 2016

Ultrathin primary is a marker for worse prognosis in lymph node-positive cutaneous melanoma

artículo científico publicado en 2013

Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma

artículo científico publicado en 2014

Vitamin D receptor upregulation in alloreactive human T cells

artículo científico publicado en 2012

Whole exome sequencing of a patient with metastatic hidradenocarcinoma and review of the literature.

artículo científico

c-MET expression in primary and liver metastases in uveal melanoma.

artículo científico publicado en 2014

Lista de obras de Richard W. Joseph

A Multidisciplinary Biospecimen Bank of Renal Cell Carcinomas Compatible with Discovery Platforms at Mayo Clinic, Scottsdale, Arizona

A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer.

A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma.

ANKS1B is a smoking-related molecular alteration in clear cell renal cell carcinoma.

Age-period-cohort analysis of renal cell carcinoma in United States adults

An integrated model of the transcriptome of HER2-positive breast cancer

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Assessing the clinical use of clear cell renal cell carcinoma molecular subtypes identified by RNA expression analysis.

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor.

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2

Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression.

Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness.

Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response.

Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced Melanoma ⬇️

Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy.

Detection of tumor-associated cells in cryopreserved peripheral blood mononuclear cell samples for retrospective analysis.

Efficacy of immunotherapy for metastatic mucosal melanoma.

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

Evaluation of the association of prostate cancer-specific anxiety with sexual function, depression and cancer aggressiveness in men 1 year following surgical treatment for localized prostate cancer.

Follicular Dendritic Cell Sarcoma Presenting As a Thyroid Mass

High incidence of vitamin D deficiency in patients undergoing allogeneic stem cell transplantation

High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma

Higher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma

Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy

Inverse association between programmed death ligand 1 and genes in the VEGF pathway in primary clear cell renal cell carcinoma

Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma

Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy.

Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma

Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma

Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death

Management of Metastatic Apocrine Hidradenocarcinoma with Chemotherapy and Radiation

NRAS mutation status is an independent prognostic factor in metastatic melanoma

Negative Sentinel Lymph Node Biopsy in Merkel Cell Carcinoma is Associated with a Low Risk of Same-Nodal-Basin Recurrences.

Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice.

Obese men have more advanced and more aggressive prostate cancer at time of surgery than non-obese men after adjusting for screening PSA level and age: results from two independent nested case-control studies

Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma

PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation

Patient-derived tumor xenograft models for melanoma drug discovery

Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team.

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma

Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab

Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Sentinel lymph node biopsy in Merkel cell carcinoma: The Mayo Clinic experience of 150 patients

Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy.

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma

Somatic expression of ENRAGE is associated with obesity status among patients with clear cell renal cell carcinoma

Steroid hormone influence on melanomagenesis

Therapy for metastatic melanoma: the past, present, and future.

Three hundred consecutive emergent celiotomies in general surgery patients: influence of advanced diagnostic imaging techniques and procedures on diagnosis

Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod

Ultrathin primary is a marker for worse prognosis in lymph node-positive cutaneous melanoma

Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma

Vitamin D receptor upregulation in alloreactive human T cells

Whole exome sequencing of a patient with metastatic hidradenocarcinoma and review of the literature.

c-MET expression in primary and liver metastases in uveal melanoma.